Grandeur Peak Global Advisors LLC lifted its stake in shares of Alpha Teknova, Inc. (NASDAQ:TKNO – Get Rating) by 2.9% during the first quarter, Holdings Channel.com reports. The firm owned 227,170 shares of the company's stock after buying an additional 6,304 shares during the period. Grandeur Peak Global Advisors LLC's holdings in Alpha Teknova were worth $3,137,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Alpha Teknova by 27.9% during the first quarter. JPMorgan Chase & Co. now owns 6,571 shares of the company's stock worth $91,000 after acquiring an additional 1,435 shares during the last quarter. Alpha Paradigm Partners LLC bought a new position in shares of Alpha Teknova during the fourth quarter worth $190,000. Parian Global Management LP acquired a new position in shares of Alpha Teknova in the 4th quarter valued at $780,000. Northern Trust Corp raised its stake in Alpha Teknova by 13.2% during the 4th quarter. Northern Trust Corp now owns 69,270 shares of the company's stock worth $1,419,000 after buying an additional 8,069 shares during the period. Finally, Ranger Investment Management L.P. grew its stake in Alpha Teknova by 18.1% in the fourth quarter. Ranger Investment Management L.P. now owns 264,446 shares of the company's stock valued at $5,416,000 after acquiring an additional 40,554 shares during the period. 24.59% of the stock is owned by institutional investors.
Get Alpha Teknova alerts:Analysts Set New Price Targets
Separately, Stephens cut their price objective on Alpha Teknova from $22.00 to $15.00 and set an "overweight" rating on the stock in a report on Thursday, August 11th.
Alpha Teknova Price Performance
NASDAQ:TKNO opened at $4.28 on Wednesday. Alpha Teknova, Inc. has a 52-week low of $3.85 and a 52-week high of $28.64. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $10.47. The company has a current ratio of 6.77, a quick ratio of 6.10 and a debt-to-equity ratio of 0.13.Alpha Teknova (NASDAQ:TKNO – Get Rating) last released its earnings results on Wednesday, August 10th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Alpha Teknova had a negative net margin of 43.93% and a negative return on equity of 13.25%. During the same period in the previous year, the firm earned ($0.52) earnings per share. As a group, sell-side analysts forecast that Alpha Teknova, Inc. will post -0.94 EPS for the current fiscal year.
Insider Buying and Selling
In other Alpha Teknova news, Director J Matthew Mackowski acquired 10,000 shares of the company's stock in a transaction on Wednesday, August 24th. The shares were purchased at an average price of $4.97 per share, for a total transaction of $49,700.00. Following the completion of the purchase, the director now directly owns 5,000 shares of the company's stock, valued at $24,850. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Stephen Gunstream bought 18,000 shares of the stock in a transaction on Monday, August 15th. The stock was acquired at an average price of $5.13 per share, with a total value of $92,340.00. Following the acquisition, the chief executive officer now directly owns 18,000 shares in the company, valued at $92,340. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director J Matthew Mackowski purchased 10,000 shares of Alpha Teknova stock in a transaction dated Wednesday, August 24th. The shares were purchased at an average price of $4.97 per share, for a total transaction of $49,700.00. Following the completion of the acquisition, the director now owns 5,000 shares of the company's stock, valued at approximately $24,850. The disclosure for this purchase can be found here. 15.20% of the stock is currently owned by corporate insiders.
About Alpha Teknova
(Get Rating)
Alpha Teknova, Inc provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Further Reading
- Get a free copy of the StockNews.com research report on Alpha Teknova (TKNO)
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
Want to see what other hedge funds are holding TKNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Teknova, Inc. (NASDAQ:TKNO – Get Rating).
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.